Critical Business Considerations for Life Sciences and Medical Device Companies Amid the COVID-19 Pandemic

Life sciences and medical device companies are dealing with an unprecedented crisis. The industry is not only managing the impact of Coronavirus (COVID-19), they are also a solution provider. Companies are rapidly adapting products, services, facilities and distribution channels to aid in the pandemic response. Simultaneously, they must maintain shareholder value, navigate highly complex regulatory hurdles and compliance obligations while rethinking strategies for growth in a post-COVID-19 world.

Join a team of seasoned professionals from McDermott Will & Emery and Ernst & Young, LLP for insights and guidance on critical COVID-19-related operational, regulatory and legal developments, including:

• Supply chain adaption and compliance
• R&D, clinical trials and the FDA
• The CARES act and accessing government funds
• Restructuring and solvency strategies

See full agenda and speaker information below.

With the flood of information available to you, we want to ensure you have the opportunity to get answers to any questions that will help you assess your particular business needs.

Please note areas where you could use additional guidance in the “Questions & Comments” box so we can address the issues that are most important to you.